Skip to main content

Research Repository

Advanced Search

Hepatitis C virus vaccine: Challenges and prospects

Duncan, Joshua D.; Urbanowicz, Richard A.; Tarr, Alexander W.; Ball, Jonathan K.

Authors

Joshua D. Duncan

JONATHAN BALL jonathan.ball@nottingham.ac.uk
Professor of Molecular Virology



Abstract

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated.

Journal Article Type Review
Publication Date Mar 1, 2020
Journal Vaccines
Electronic ISSN 2076-393X
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 8
Issue 1
Article Number 90
APA6 Citation Duncan, J. D., Urbanowicz, R. A., Tarr, A. W., & Ball, J. K. (2020). Hepatitis C virus vaccine: Challenges and prospects. Vaccines, 8(1), https://doi.org/10.3390/vaccines8010090
DOI https://doi.org/10.3390/vaccines8010090
Keywords hepatitis C virus; vaccines; neutralising antibodies; animal models; immune responses
Publisher URL https://www.mdpi.com/2076-393X/8/1/90
;